Custom Synthesis of Polyphosphates and Phosphoramidites

The increasing number of dedicated high-tech, science-based businesses has been one of the few ‘good news’ items in the world economy in recent years; businesses like TriLink. 

TriLink Biotechnologies have a deserved reputation as an outstanding exponent of custom oligonucleotide and nucleoside triphosphate manufacturing. The Trilink scientists and technologists have accumulated a vast wealth of expertise in this area of custom synthesis; one that has expanded rapidly in the decades following the first directed oligo synthesis (a dithymidinyl nucleotide) in 1955. Their experience in modified nucleic acid products helps ensure the best possible results for clients in a number of the rapidly multiplying biotechnology-related fields.

The full weight of their experience and skill has been brought to bear on the synthesis of polyphosphates and phosphoramidites. 

If you require polyphosphates, TriLink are not only able to offer 150 modified nucleotides from stock, but their custom polyphosphate synthesis service can produce mono-, di- and triphosphates, as required, to your specifications, even if there is currently no known synthesis scheme; such is their confidence in their skill. Lead times range from just 4 – 8 weeks and if you do not have your own nucleoside, or it is not commercially available TriLink can prepare that as well.

If your need is for a particular phosphoramidite, Trilink can not only make it; they can incorporate it into an oligonucleotide for you. As with their polyphosphate synthesis, all products undergo multiple analysis with yields matched to your requirements, imbuing confidence and allowing you to concentrate on your research and experimentation. TriLink, as oligonucleotide chemists, know how important it is for you to have the right tools, such as high quality like DNA synthesis reagents, to ensure your success.  

TriLink’s top chemists still continue to address today’s challenges, such as the need for better high-throughput methods for the PCR and screening markets, improving dye modified oligonucleotides for diagnostics and producing greater quantities of modified oligonucleotides for therapeutic needs and that has got to be good news.  

Date added: 2015-05-25 11:42:11